Zur Rose Group

E-pharmacy Market revenue worth $206 Billion by 2028, Says Global Market Insights Inc.

Retrieved on: 
Wednesday, February 23, 2022
Giant, Conditional sentence, CVS Health, Pharmacy, Internet, Giant Eagle, Walgreens, Industry, Renewable energy, Walmart, Medicine, Adoption, Zur Rose Group, USD, Research report, Biotechnology, Express Scripts, Patient, Technology, CAGR, Research, Online shopping, Distribution (marketing), Healthcare, UnitedHealth Group

SELBYVILLE, Del., Feb. 23, 2022 /PRNewswire/ -- Global E-pharmacy market value is anticipated to cross USD 206 billion by 2028, according to a new research report by Global Market Insights Inc. Increasing adoption of digital technologies and e-commerce platforms in the pharmaceutical industry is anticipated to spur the market growth.

Key Points: 
  • SELBYVILLE, Del., Feb. 23, 2022 /PRNewswire/ -- Global E-pharmacy market value is anticipated to cross USD 206 billion by 2028, according to a new research report by Global Market Insights Inc. Increasing adoption of digital technologies and e-commerce platforms in the pharmaceutical industry is anticipated to spur the market growth.
  • Entry of new players with focus on the development of digital health technologies further favors the industry growth.
  • Global Market Insights Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services.
  • Our business intelligence and industry research reports offer clients with penetrative insights and actionable market data specially designed and presented to aid strategic decision making.

EQS-News: Zur Rose Group: steady growth in a volatile market environment

Retrieved on: 
Thursday, January 20, 2022
People, City, Patient, Zur Rose Group, Intention, EBITDA, Plasma protein binding, Pharmacy, Partnership, Federal Ministry of Health (Germany), Growth, Telehealth, Annual, Automation, Obesity, Acquisition, Acceleration, Beauty, OTC, Diabetes, CHF, FMH, B2C, Novo Nordisk, Annual report, Professional services, Pharmaceutical industry, Health insurance, Group, Health, Apote

External revenue rose to CHF 2,034.1 million, equivalent to growth of 15.5 per cent in Group currency terms or 14.8 per cent in local currency terms.

Key Points: 
  • External revenue rose to CHF 2,034.1 million, equivalent to growth of 15.5 per cent in Group currency terms or 14.8 per cent in local currency terms.
  • In Germany the Zur Rose Group posted a considerable rise in external revenue in 2021, up 19.4 per cent in local currency terms.
  • Zur Rose continued to expand digital services both for doctors' practices and in the B2C business.
  • Like all other stakeholders, the Zur Rose Group expects the binding schedule to be announced as soon as possible.

EQS-News: Zur Rose Group nominates Rongrong Hu as director

Retrieved on: 
Monday, January 10, 2022
Health, Engineering, Pharmacy, McKinsey & Company, SIX Swiss Exchange, Zur Rose Group, Beauty, Shanghai Jiao Tong University, MBA, Patient, ROSE, Board, Female, EBay, CHF, Board of directors, Harvard Business School, Company, Technology, ISIN, Mass meeting, Telecommunications engineering, Business development, International economics, Management

The Board of Directors of the Zur Rose Group has decided to propose Rongrong Hu for election as a new member at the General Meeting of Shareholders on 28 April 2022.

Key Points: 
  • The Board of Directors of the Zur Rose Group has decided to propose Rongrong Hu for election as a new member at the General Meeting of Shareholders on 28 April 2022.
  • Rongrong Hu, a 41-year-old Chinese national, has been living in Switzerland since 2016 and is an investor focusing on the technology sector.
  • The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland.
  • The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE).

DGAP-News: SynBiotic SE and key.force: Joint Venture for Germany's largest cannabis sales team

Retrieved on: 
Tuesday, December 21, 2021
Gesellschaft mit beschränkter Haftung, EU, DGAP, Physician, Pain, CEO, Zur Rose Group, Sleep, Marketing, Cannabis, Research, SE, Industry, News, Pharmacy, Synbiotics, Anxiety, Sale, Patient, Security (finance), Drug, Medicinal plants

- With canna.sales GmbH, the leading platform for market access, sales & marketing of products and supply services in the field of medical cannabis is established

Key Points: 
  • - With canna.sales GmbH, the leading platform for market access, sales & marketing of products and supply services in the field of medical cannabis is established
    Germany's most powerful cannabis sales team: SynBiotic SE and key.force GmbH found the joint venture canna.sales GmbH.
  • The sales company key.force, established with leading pharmaceutical companies, is already very successful in the field of medical cannabis.
  • With a nationwide sales force, key account management and medical science liaison managers, the key.force sales team has excellent contacts to cannabis prescribers, pharmacies, health insurance companies and professional stakeholders.
  • SynBiotic SE is the largest listed group in Europe in the hemp and cannabis sector and pursues an EU-focused buy & build investment strategy.

EQS-News: Zur Rose and the Swiss Association for the Blind and Visually Impaired make it easier for people with a visual impairment to take medication

Retrieved on: 
Monday, December 20, 2021
Smartphone, Perforation, QR, Swiss association, Severe cognitive impairment, Pharmacy, SBV, Life, Visual impairment, Awareness, Pegasos Swiss Association, Zur Rose Group, DailyMed, Time, Blind, Patient, Mark (given name), Technology, Health, Medical device

In collaboration with the Swiss Association for the Blind and Visually Impaired (SBV), Zur Rose is therefore adapting its medications box for individually sorted and packaged medications to the special needs of people with a visual impairment and providing barrier-free access to medication information.

Key Points: 
  • In collaboration with the Swiss Association for the Blind and Visually Impaired (SBV), Zur Rose is therefore adapting its medications box for individually sorted and packaged medications to the special needs of people with a visual impairment and providing barrier-free access to medication information.
  • Together with the SBV, online pharmacy Zur Rose has therefore adapted its individually blister-packaged Dailymed box specially for the needs of people with a visual impairment.
  • Zur Rose is using some of the proceeds from the specially developed medications box to support projects by the Swiss Association for the Blind and Visually Impaired to make daily life easier for people with a visual impairment.
  • The Swiss Association for the Blind and Visually Impaired (SBV) is the national self-help organisation for visual impairment.

Applebee’s® Recognizes Restaurant Performance, Innovation and Community Engagement at Annual Franchise Conference

Retrieved on: 
Monday, November 22, 2021
Supply Chain Management, Family, Retail, Consumer, Restaurant, Bar, Food, Beverage, CEO, General officer, Doherty, Reed, Avalon (American group), NYSE, General manager, Franchise, Year, NRP, Program, Family, Restaurant, Love, Applebee, Zur Rose Group, AAG, Culture, Human, Friends, Organic, Food, Multimedia, Growth, Pharmaceutical industry

Last week, Applebee's Neighborhood Grill + Bar held their annual franchise conference in Scottsdale, Ariz. to celebrate triumphs, recognize excellent restaurant performance and community involvement, and outline plans for future growth and performance.

Key Points: 
  • Last week, Applebee's Neighborhood Grill + Bar held their annual franchise conference in Scottsdale, Ariz. to celebrate triumphs, recognize excellent restaurant performance and community involvement, and outline plans for future growth and performance.
  • This new scholarship program aims to award 100 scholarships annually to current Applebees restaurant team members and their children.
  • This new scholarship program will allow team members working for Applebees and their children the opportunity to continue their education.
  • From raising money for local charities to hosting community fundraisers, Applebees is always Doin Good in the Neighborhood.

EQS-News: Roche and the Zur Rose Group announce collaboration to offer innovative health journeys for people living with diabetes

Retrieved on: 
Thursday, October 28, 2021
People, Pharmacy, Quality of life, Technology, SIX Swiss Exchange, Ecosystem, Disease, ISIN, Zur Rose Group, Conditional sentence, Type 2 diabetes, Caregiver, Patient, EHealth, Roche, Telehealth, Mark (given name), CHF, CEO, Diabetes, Solution, Beauty, Health, ROSE, Population, Prevalence, Pharmaceutical industry

As part of the collaboration, Roche Diabetes Care and the Zur Rose Group are connecting their healthcare products and solutions and those of best-in-class third parties to improve the lives of people with diabetes.

Key Points: 
  • As part of the collaboration, Roche Diabetes Care and the Zur Rose Group are connecting their healthcare products and solutions and those of best-in-class third parties to improve the lives of people with diabetes.
  • As a global leader in integrated Personalised Diabetes Management, Roche Diabetes Care aims to drive sustainable care to improve the lives of people with diabetes.
  • Segment Germany of the Zur Rose Group:
    The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland.
  • The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE).

Roche and the Zur Rose Group announce collaboration to offer innovative health journeys for people living with diabetes

Retrieved on: 
Thursday, October 28, 2021
People, Chek, Glucose, Quality of life, Third party, Ecosystem, Essential medicines, Disease, Zur Rose Group, RO, Conditional sentence, Type 2 diabetes, Dow Jones, Hoffmann-La Roche, Caregiver, Joint Medical Service (Germany), World, EHealth, Genentech, Telehealth, Mark (given name), Risk, DJSI, List, CHF, Infection, CEO, ROG, Pharmaceutical industry, Diabetes, Solution, Population, Central nervous system, Prevalence, Ophthalmology, Medical device, Fine chemical

It will focus primarily on people living with type 2 diabetes, which accounts for about 90% of all cases.1

Key Points: 
  • It will focus primarily on people living with type 2 diabetes, which accounts for about 90% of all cases.1
    As a global leader in integrated Personalised Diabetes Management, Roche Diabetes Care aims to drive sustainable care to improve the lives of people with diabetes.
  • With its pharmaceutical experts, eHealth and pharmacy platforms, telemedicine and technology expertise, and consumer reach, the Zur Rose Group will bring convenient and personalised diabetes journeys to life seamlessly connecting health products and solutions.
  • Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years.
  • Since 2017, mySugr, one of the most popular diabetes management apps, has been part of Roche Diabetes Care.

Roche and the Zur Rose Group announce collaboration to offer innovative health journeys for people living with diabetes

Retrieved on: 
Thursday, October 28, 2021
People, Chek, Glucose, Quality of life, Third party, Ecosystem, Essential medicines, Disease, Zur Rose Group, RO, Conditional sentence, Type 2 diabetes, Dow Jones, Hoffmann-La Roche, Caregiver, Joint Medical Service (Germany), World, EHealth, Genentech, Telehealth, Mark (given name), Risk, DJSI, List, CHF, Infection, CEO, ROG, Pharmaceutical industry, Diabetes, Solution, Population, Central nervous system, Prevalence, Ophthalmology, Medical device, Fine chemical

It will focus primarily on people living with type 2 diabetes, which accounts for about 90% of all cases.1

Key Points: 
  • It will focus primarily on people living with type 2 diabetes, which accounts for about 90% of all cases.1
    As a global leader in integrated Personalised Diabetes Management, Roche Diabetes Care aims to drive sustainable care to improve the lives of people with diabetes.
  • With its pharmaceutical experts, eHealth and pharmacy platforms, telemedicine and technology expertise, and consumer reach, the Zur Rose Group will bring convenient and personalised diabetes journeys to life seamlessly connecting health products and solutions.
  • Roche Diabetes Care has been pioneering innovative diabetes technologies and services for more than 40 years.
  • Since 2017, mySugr, one of the most popular diabetes management apps, has been part of Roche Diabetes Care.

EQS-News: Zur Rose Group strengthens Group Management: Madhu Nutakki to become Chief Technology Officer

Retrieved on: 
Tuesday, June 15, 2021
Countries, Companies, Zur Rose Group, American International Group, Chief technology officer, SWITZERLAND, Economy of New York City

Zur Rose Group strengthens Group Management: Madhu Nutakki to become Chief Technology Officer

Key Points: 
  • Zur Rose Group strengthens Group Management: Madhu Nutakki to become Chief Technology Officer
    Zur Rose Group strengthens Group Management: Madhu Nutakki to become Chief Technology Officer
    Madhu Nutakki will take on the newly created position of Chief Technology Officer (CTO) of the Zur Rose Group on 1 August 2021.
  • Previously, he worked at American International Group (AIG) insurance company in New York, USA, for three years as Chief Technology Officer and Global Digital Head.
  • The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland.
  • The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE).